CN105324126A - Glp-1受体激动剂在用胰岛素治疗的和/或患有1型糖尿病的患者中的新用途 - Google Patents

Glp-1受体激动剂在用胰岛素治疗的和/或患有1型糖尿病的患者中的新用途 Download PDF

Info

Publication number
CN105324126A
CN105324126A CN201480034511.3A CN201480034511A CN105324126A CN 105324126 A CN105324126 A CN 105324126A CN 201480034511 A CN201480034511 A CN 201480034511A CN 105324126 A CN105324126 A CN 105324126A
Authority
CN
China
Prior art keywords
glp
receptor agonist
hypoglycemia
alternative
additional embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201480034511.3A
Other languages
English (en)
Chinese (zh)
Inventor
E.克里斯蒂安森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of CN105324126A publication Critical patent/CN105324126A/zh
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201480034511.3A 2013-06-21 2014-06-23 Glp-1受体激动剂在用胰岛素治疗的和/或患有1型糖尿病的患者中的新用途 Withdrawn CN105324126A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361837988P 2013-06-21 2013-06-21
US61/837988 2013-06-21
EP13173316.4 2013-06-21
EP13173316 2013-06-21
PCT/EP2014/063115 WO2014202780A1 (en) 2013-06-21 2014-06-23 Novel uses of glp-1 receptor agonists in patients treated with insulin and/or suffering from type 1 diabetes

Publications (1)

Publication Number Publication Date
CN105324126A true CN105324126A (zh) 2016-02-10

Family

ID=48655995

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480034511.3A Withdrawn CN105324126A (zh) 2013-06-21 2014-06-23 Glp-1受体激动剂在用胰岛素治疗的和/或患有1型糖尿病的患者中的新用途

Country Status (5)

Country Link
US (1) US20160136246A1 (enExample)
EP (1) EP3010531A1 (enExample)
JP (1) JP2016522241A (enExample)
CN (1) CN105324126A (enExample)
WO (1) WO2014202780A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110650747A (zh) * 2017-06-01 2020-01-03 伊莱利利公司 用于治疗慢性肾病的杜拉鲁肽
CN112312922A (zh) * 2018-06-21 2021-02-02 诺和诺德股份有限公司 用于治疗肥胖症的新型化合物

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105832691B (zh) * 2016-05-31 2018-10-02 深圳市健元医药科技有限公司 一种度拉糖肽结肠定位缓释制剂及其制备方法
HUE060149T2 (hu) * 2016-12-16 2023-02-28 Novo Nordisk As Inzulint tartalmazó gyógyászati készítmények
EP3474820B1 (en) 2017-08-24 2024-02-07 Novo Nordisk A/S Glp-1 compositions and uses thereof
TWI705820B (zh) 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
US20220315632A1 (en) 2019-03-15 2022-10-06 Diet4Life Aps Combination of dietary peptides
WO2021142733A1 (en) * 2020-01-16 2021-07-22 Shanghai Benemae Pharmaceutical Corporation Combinational therapy comprising glp-1 and/or glp-1 analogs, and insulin and/or insulin analogs
PE20230819A1 (es) * 2020-02-18 2023-05-19 Novo Nordisk As Composiciones y usos de glp-1

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2723359A4 (en) * 2011-06-24 2015-03-11 Amylin Pharmaceuticals Llc METHOD FOR THE TREATMENT OF DIABETES WITH THE HELP OF DELAYED RELEASED FORMULATIONS FROM GLP-1 RECEPTOR AGONISTS

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110650747A (zh) * 2017-06-01 2020-01-03 伊莱利利公司 用于治疗慢性肾病的杜拉鲁肽
CN112312922A (zh) * 2018-06-21 2021-02-02 诺和诺德股份有限公司 用于治疗肥胖症的新型化合物
US11753455B2 (en) 2018-06-21 2023-09-12 Novo Nordisk A/S Compounds for treatment of obesity

Also Published As

Publication number Publication date
WO2014202780A1 (en) 2014-12-24
JP2016522241A (ja) 2016-07-28
EP3010531A1 (en) 2016-04-27
US20160136246A1 (en) 2016-05-19

Similar Documents

Publication Publication Date Title
AU2020202573B2 (en) Use of long-acting GLP-1 peptides
US9486506B2 (en) Glucagon analogues
CN105324126A (zh) Glp-1受体激动剂在用胰岛素治疗的和/或患有1型糖尿病的患者中的新用途
US8481490B2 (en) Method of reducing plasma amylase and/or plasma lipase in patients with pancreatitis
KR102460198B1 (ko) 비만 치료를 위한 글루카곤 및 glp-1 공동-작용제
JP2005508895A (ja) Ｇｌｐ−１および基礎インスリンの予備混合物
Karras et al. The effects of incretins on energy homeostasis: physiology and implications for the treatment of type 2 diabetes mellitus and obesity
Jing et al. Biological activity studies of the novel glucagon-like peptide-1 derivative HJ07

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication

Application publication date: 20160210

WW01 Invention patent application withdrawn after publication